All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Mitsubishi, Astellas partner to support pharma startups in Japan
The initiative is part of the Ministry of Health, Labour and Welfare’s Medical Innovation Support Office (MEDISO) programme, which seeks to apply Japan’s advanced life-sciences technologies practically.
J&J unveils promising data for dual-targeting CAR T therapy
The investigational therapy JNJ-4496, formerly known as C-CAR039, is being tested in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not previously received CAR T-cell therapy
BioNTech to acquire mRNA drugmaker CureVac for up to $1.25bn
The German biotech firm plans to integrate CureVac’s research and manufacturing site in Tübingen into its operations, and its expertise in the research, development, and marketing of mRNA-based cancer immunotherapy.
Moderna secures FDA expanded approval for mRESVIA RSV vaccine
The FDA approval was based on results from Moderna’s Phase 3 study, which assessed the vaccine’s safety and immunogenicity in adults aged 18-59 with underlying health conditions.
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk.
Echosens, Boehringer Ingelheim expand collaboration for MASH care
The expanded collaboration will focus on increasing awareness of MASH among patients, healthcare professionals, and policymakers, with emphasis on the urgent need for early screening and diagnosis.
Jazz secures FDA priority review for Zepzelca-Tecentriq combination
The US regulator accepted the biopharmaceutical company’s supplemental New Drug Application (sNDA) for this combination therapy, indicated for the treatment of extensive-stage small cell lung cancer (ES-SCLC)
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement
Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its royalty rights on global net sales of ZYNYZ
Alnylam gains EC approval for Amvuttra in ATTR amyloidosis
The EC approval, which follows the Committee for Orphan Medicinal Products’ positive opinion, expands Amvuttra’s indication to include hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)
Merck reports positive Phase 3 results for Enlicitide in hyperlipidemia
The CORALreef HeFH and CORALreef AddOn trials showed statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) compared to placebo and other oral non-statin therapies.